Key facts
- It has raised $340K; the latest was Early Stage VC ($140K) in Sep 2025.
- Notable investors include Leave a Nest Capital, Japan System Techniques.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Regenesome
- ·The full record, as it builds
Funding rounds
No funding rounds for Regenesome are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Regenesome
Developer of anti-ageing technology intended to develop supplements, foods and cosmetics that utilize exosomes. The company specializes in developing healthcare products that utilize exosome analysis technology and advancing medical field technology, enabling clients to help solve the challenges of aging and advance longevity through biotechnology.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2024
- Website
- regenesome.com/
- Ownership
- Privately Held (backing)
Regenesome doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Regenesome shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Regenesome in its N-PORT filings yet. We sweep new filings monthly.